Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
Lisa R. Young, Hye Seung Lee, Yoshikazu Inoue, Joel Moss, Lianne G. Singer, Charlie Strange, Koh Nakata, Alan F. Barker, Jeffrey T. Chapman, Mark L. Brantly, James M. Stocks, Kevin K. Brown, Joseph P. Lynch, Hilary J. Goldberg, Gregory P. Downey, Jeffrey J. Swigris, Angelo M. Taveira-DaSilva, Jeffrey P. Krischer, Bruce C. Trapnell, Francis X. McCormack
Dive into the research topics of 'Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial'. Together they form a unique fingerprint.